Journal Mobile Options
Table of Contents
7, No. 6, 2012
Issue release date: December 2012
Free Access
Breast Care 2012;7:439–444
(DOI:10.1159/000345867)

Present Status of Adjuvant Chemotherapy for Elderly Breast Cancer Patients

Loibl S.a,b · Reinisch M.a,c
aGerman Breast Group, Neu-Isenburg, bStädtische Kliniken Offenbach, cFrauenklinik, Bürgerhospital Frankfurt/M., Germany
email Corresponding Author

Abstract

Elderly breast cancer patients are underrepresented in clinical trials, leading to a lack of knowledge regarding their tolerance of modern chemotherapy regimens. In addition, physicians are often reluctant to treat older patients with chemotherapy due to potential side effects. This article summarizes the up-to-date literature on chemotherapy in elderly patients with breast cancer, evaluates the impact of the patients’ comorbidities and treatment alterations and aims to encourage treating patients adequately according to their disease in combination with the biological age rather than the chronological age alone. Finally, a short overview is given of the recruiting studies in Europe evaluating chemotherapy in elderly patients.


 Outline


 goto top of outline Keywords

  • Adjuvant chemotherapy
  • Elderly patients
  • Breast cancer

 goto top of outline Summary

Elderly breast cancer patients are underrepresented in clinical trials, leading to a lack of knowledge regarding their tolerance of modern chemotherapy regimens. In addition, physicians are often reluctant to treat older patients with chemotherapy due to potential side effects. This article summarizes the up-to-date literature on chemotherapy in elderly patients with breast cancer, evaluates the impact of the patients’ comorbidities and treatment alterations and aims to encourage treating patients adequately according to their disease in combination with the biological age rather than the chronological age alone. Finally, a short overview is given of the recruiting studies in Europe evaluating chemotherapy in elderly patients.


 goto top of outline Author Contacts

Prof. Dr. med. Sibylle Loibl
GBG Forschungs GmbH
Martin Behaim Strasse 12
63263 Neu-Isenburg, Germany
Sibylle.Loibl@germanbreastgroup.de


 goto top of outline Article Information

Published online: December 14, 2012
Number of Print Pages : 6


 goto top of outline Publication Details

Breast Care (Multidisciplinary Journal for Research, Diagnosis and Therapy)

Vol. 7, No. 6, Year 2012 (Cover Date: December 2012)

Journal Editor: Harbeck N. (München), Thomssen C. (Halle/Saale), Gnant M. (Wien)
ISSN: 1661-3791 (Print), eISSN: 1661-3805 (Online)

For additional information: http://www.karger.com/BRC


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Abstract

Elderly breast cancer patients are underrepresented in clinical trials, leading to a lack of knowledge regarding their tolerance of modern chemotherapy regimens. In addition, physicians are often reluctant to treat older patients with chemotherapy due to potential side effects. This article summarizes the up-to-date literature on chemotherapy in elderly patients with breast cancer, evaluates the impact of the patients’ comorbidities and treatment alterations and aims to encourage treating patients adequately according to their disease in combination with the biological age rather than the chronological age alone. Finally, a short overview is given of the recruiting studies in Europe evaluating chemotherapy in elderly patients.



 goto top of outline Author Contacts

Prof. Dr. med. Sibylle Loibl
GBG Forschungs GmbH
Martin Behaim Strasse 12
63263 Neu-Isenburg, Germany
Sibylle.Loibl@germanbreastgroup.de


 goto top of outline Article Information

Published online: December 14, 2012
Number of Print Pages : 6


 goto top of outline Publication Details

Breast Care (Multidisciplinary Journal for Research, Diagnosis and Therapy)

Vol. 7, No. 6, Year 2012 (Cover Date: December 2012)

Journal Editor: Harbeck N. (München), Thomssen C. (Halle/Saale), Gnant M. (Wien)
ISSN: 1661-3791 (Print), eISSN: 1661-3805 (Online)

For additional information: http://www.karger.com/BRC


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.